Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, 3010, VIC, Australia.
Bio21 Molecular Science & Biotechnology Institute, University of Melbourne, Parkville, 3010, VIC, Australia.
Chemistry. 2020 Sep 10;26(51):11796-11805. doi: 10.1002/chem.202000642. Epub 2020 Aug 18.
The structural poses of ligands that bind weakly to protein receptors are challenging to define. In this work we have studied ligand interactions with the adrenoreceptor (AR) subtypes, α -AR and α -AR, which belong to the G protein-coupled receptor (GPCR) superfamily, by employing the solution-based ligand-observed NMR method interligand NOEs for pharmacophore mapping (INPHARMA). A lack of receptor crystal structures and of subtype-selective drugs has hindered the definition of the physiological roles of each subtype and limited drug development. We determined the binding pose of the weakly binding α -AR-selective agonist A-61603 relative to an endogenous agonist, epinephrine, at both α -AR and α -AR. The NMR experimental data were quantitatively compared, by using SpINPHARMA, to the back-calculated spectra based on ligand poses obtained from all-atom molecular dynamics simulations. The results helped mechanistically explain the selectivity of (R)-A-61603 towards α -AR, thus demonstrating an approach for targeting subtype selectivity in ARs.
配体与蛋白质受体弱结合的结构构象难以确定。在这项工作中,我们通过使用基于溶液的配体观察 NMR 方法(ligand-observed NMR method)——互配体 NOE 用于药效团作图(interligand NOEs for pharmacophore mapping,INPHARMA),研究了配体与肾上腺素能受体(adrenoreceptor,AR)亚型 α 1 -AR 和 α 2 -AR 的相互作用,这两种受体都属于 G 蛋白偶联受体(G protein-coupled receptor,GPCR)超家族。缺乏受体晶体结构和亚型选择性药物阻碍了对每种亚型的生理作用的定义,并限制了药物的开发。我们确定了弱结合的 α 1 -AR 选择性激动剂 A-61603 与内源性激动剂肾上腺素在 α 1 -AR 和 α 2 -AR 上的结合构象。通过使用 SpINPHARMA,对基于从全原子分子动力学模拟获得的配体构象计算得出的光谱进行了定量比较,从而对 NMR 实验数据进行了比较。结果有助于从机制上解释(R)-A-61603 对 α 1 -AR 的选择性,从而证明了一种针对 AR 亚型选择性的方法。